Age: 78.0
Sex: M
Vaccine: COVID19
Symptoms: Cognitive disorder, Fatigue, Polychondritis
Clinical narrative: cognitive limitations; relapsing polychondritis; slightly tired; This spontaneous case was reported by a nurse and describes the occurrence of POLYCHONDRITIS (relapsing polychondritis) in a 78-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     Concurrent medical conditions included Penicillin allergy.    In October 2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In October 2021, the patient experienced FATIGUE (slightly tired). In November 2021, the patient experienced POLYCHONDRITIS (relapsing polychondritis) (seriousness criterion medically significant). On an unknown date, the patient experienced COGNITIVE DISORDER (cognitive limitations). The patient was treated with PREDNISONE (oral) for Adverse event, at an unspecified dose and frequency. At the time of the report, POLYCHONDRITIS (relapsing polychondritis), COGNITIVE DISORDER (cognitive limitations) and FATIGUE (slightly tired) had not resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant product use was not provided by the reporter.   The patient had cognitive limitations. The patient had all the shots. The patient never had COVID positive test or diagnosis, was systemically very healthy, and did not receive any other vaccines within 1 month prior to Moderna COVID-19 vaccine. He had his booster in Oct-2021, had no initial reaction other than slightly tired. In Nov-2021, the patient had first symptoms of relapsing polychondritis about 3 weeks after booster. He had symptoms from Nov-2021 through May-2022, was diagnosed with relapsing polychondritis in May-2022. It was very hard to diagnose, this was autoimmune response on a 78-year-old body due to the vaccine. The patient would start an infusion of Remicade which would be ongoing life sentence. The patient did not experience a similar event in the past.  Company Comment: This spontaneous case concerns a 78 year old male patient with no relevant medical history reported , who experienced Serious ( medically significant ) , unexpected event of polychondritis ( relapsing polychondritis) which occurred approximately 1 month post vaccination with the dose 3 of mRNA-1273 vaccine, The information regarding the Dose 1 and Dose 2 Covid 19 Vaccine  of this patient was not reported. Other non-serious , unexpected event of cognitive disorder and non-serious , expected event of fatigue was also experienced by this patient . This patient had no other problem with his booster vaccine but only  fatigue initially then around Nov. 2021 started to have symptoms and was then diagnosed with Polychondritis on May 2022. This patient was said to have made ER visit .    He was treated with oral  prednisone and would start an infusion with Remicade.  Results of laboratories/diagnostic procedures were not provided. Outcome of the events was reported as not resolved. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.; Sender's Comments: This spontaneous case concerns a 78 year old male patient with no relevant medical history reported , who experienced Serious ( medically significant ) , unexpected event of polychondritis ( relapsing polychondritis) which occurred approximately 1 month post vaccination with the dose 3 of mRNA-1273 vaccine, The information regarding the Dose 1 and Dose 2 Covid 19 Vaccine  of this patient was not reported. Other non-serious , unexpected event of cognitive disorder and non-serious , expected event of fatigue was also experienced by this patient . This patient had no other problem with his booster vaccine but only  fatigue initially then around Nov. 2021 started to have symptoms and was then diagnosed with Polychondritis on May 2022. This patient was said to have made ER visit .    He was treated with oral  prednisone and would start an infusion with Remicade.  Results of laboratories/diagnostic procedures were not provided. Outcome of the events was reported as not resolved. The benefit -risk relationship of mRNA -1273 ( Moderna Covid 19 Vaccine) is not affected by this report.